17,261 trials
Colorectal Cancer · Cholangiocarcinoma
Primary: Number of Patients Requiring Stent Replacements — 1; 2; 1; 14 Participants
Adjustment Disorder With Anxious Mood
Primary: Hamilton Anxiety Scale (HAM-A) Score — -12.5; -12.6 score on a scale — p=0.9338
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Resectable Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Ductal Adenocarcinoma
Primary: Pathologic Complete Response (pCR) Rate — 0; 0 Percentage of participants
Childhood-Onset Fluency Disorder
Primary: Change From Baseline to End of 6 Weeks in Total MLGSSS — -7.0; -5.5 Score on a scale
Kohlmeier Degos Disease With Neurologic Involvement · Kohlmeier-Degos Disease
Primary: Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib — 1; 0; 0 Participants
Fibrous Dysplasia Of Bone
Primary: Proportion of Participants With Serum Phosphate Levels Within the Target Range at Week 48 — 1 Proportion of participant
Human Immunodeficiency Virus 1 Positive · Skin Kaposi Sarcoma
Primary: Overall Response Rate — 0.577 proportion of participants
Sleep Insufficiency
Primary: Mean Within-Subject Difference in Daily Sleep Duration — 0.10; 3.45; 1.74; 0.43 minutes per day
Advanced Melanoma
Primary: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization — 7.9; 8.3 months — p=0.3284
Advanced Solid Tumor Malignancy
Primary: Type and Number of Adverse Events (AEs) — 24; 37; 62; 143 number of events
Hidradenitis Suppurativa
Primary: Period A (DB Period): Percentage of Biologic and Small Molecule Immunosuppressive-Naïve Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) at…
Advanced Primary Liver Cancer · Advanced Biliary Tract Carcinoma
Primary: The Safety and Tolerability — 28; 34; 92; 3 participants
Hemolytic Disease of the Fetus and Newborn
Primary: Number of Maternal Participants With Treatment-emergent Adverse Events (TEAEs) — 3; 2; 4; 4 Participants
Symptomatic Knee Osteoarthritis
Primary: Change From Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Subscale — 21.7; 16.7 score on scale — p=0.0872